Skip to main content

Posts tagged with "Drug Industry History"

  • Business and Markets

    Another Take on the Munos Paper

    Eric Milgram over at PharmaConduct has an excellent post up on the same paper I’ve been discussing this morning. As another guy who’s been around the block a few times in this industry, he’s struck by many of the same points I am (to the point of also linking to Wikepedia’s page on Poisson distributions!) Read More
  • Business and Markets

    Munos On Big Companies and Small Ones

    So that roughly linear production of new drugs by Pfizer, as shown in yesterday’s chart, is not an anomaly. As the Bernard Munos article I’ve been talking about says: Surprisingly, nothing that companies have done in the past 60 years has affected their rates of new-drug production: whether large or small, focused on small molecules… Read More
  • Business and Markets

    Pfizer’s R&D Productivity

    Courtesy of Bernard Munos, author of the Nature Reviews article that I began blogging about yesterday, comes this note about Pfizer’s track record with new molecules. His list of Pfizer NMEs since 2000 is Geodon (ziprasidone, 2001), Vfend (voriconazole, 2002, from Vicuron – whoops, not so, this one’s Pfizer’s), Relpax (eletr… Read More
  • Business and Markets

    Drug Companies Since 1950

    There’s a data-rich paper out in Nature Reviews Drug Discovery on the history of drug innovation in the industry. I’ll get to its real conclusions in another upcoming post, but some of the underlying data are worth a post of their own. The author (Bernard Munos of Lilly) looks at new drug approvals (NMEs) since… Read More
  • Drug Assays

    Why Don’t We Have More Protein-Protein Drug Molecules?

    Almost all of the drugs on the market target one or more small-molecule binding sites on proteins. But there’s a lot more to the world than small-molecule binding sites. Proteins spend a vast amount of time interacting with other proteins, in vital ways that we’d like to be able to affect. But those binding events… Read More
  • Business and Markets

    Against Panic

    With the waves of layoffs going on, and all the nasty structural changes we’re seeing in this business, it’s easy to start feeling a toxic combination of fear and despair. And while I understand that, I’m going to try to briefly argue against it. (1) I think that, in the years to come, that people… Read More
  • Business and Markets

    Thoughts on What Used to Be Schering-Plough

    So what are we up to now, Day Three of Greater Merck? The merger with Schering-Plough went through earlier this week, and you won’t get any more numbers by searching the stock tickers for SGP. I find that weird, since I started my career there in the late 1980s/early 1990s. But while I was there… Read More
  • Business and Markets

    In Which You Get to Hear the Phrase “Hatch-Waxman” Again

    There’s a constant running battle in the drug industry between the two kinds of pharmaceutical companies: the ones who discover the drugs first, and the ones who sell the drugs cheaply after the patents have expired. It surprises me still how many people I run into (outside my work) who don’t make that distinction, or… Read More
  • Business and Markets

    Fifty Years of Scientific History For You

    Here’s a most interesting graph from the latest issue of Nature Reviews Drug Discovery. It’s from an article on trying to discern trends from broad-scale literature analysis, and it’s worth a separate blog post of its own (coming shortly). But after yesterday’s discussion of whether there are too many graduates in science an… Read More
  • Business and Markets

    You Mean You Don’t Have to Buy Them?

    Johnson & Johnson’s CEO has given an interview to the Financial Times explaining his company’s strategy with acquisitions. And right now, that strategy is. . .not to make acquisitions. They see partnerships as making a lot more sense: “The cost of developing compounds has become so high and become so risky that we are looking… Read More